Youcare Pharmaceutical’s HKEX IPO Application Lapses; Focused on Novel Modalities Including Oligonucleotide and mRNA Therapies
NewTimeSpace News: As disclosed by HKEX, the Main Board listing application of Youcare Pharmaceutical Group Co., Ltd. (688658.SH), filed on December 5, 2025, has recently lapsed after the six-month validity period expired. CITIC Securities served as the sole sponsor upon submission. The biopharma firm concentrates on four therapeutic modalities: oligonucleotides, mRNA vaccines, peptides and innovative traditional Chinese medicines.
NewTimeSpace News: Per HKEX official filings, Youcare Pharmaceutical’s Main Board IPO application submitted on 5 December 2025 has lapsed upon expiry of the statutory six-month review window, with CITIC Securities acting as the original sole sponsor.
Founded in 2001, Youcare is a biopharmaceutical enterprise engaged in the R&D, manufacturing and commercialization of four major therapeutic categories: oligonucleotides, mRNA vaccines, peptide drugs and innovative TCM medicines. Starting its business with generic chemical drugs, the company later expanded into proprietary Chinese medicine preparations and small-molecule innovative pharmaceuticals, and in recent years has built up its pipeline of novel drug candidates covering oligonucleotide, mRNA and peptide new modalities.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
